Clinical Trial

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? * How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-19
Trial Details
NCT Number NCT07197762
Lead Sponsor Emory University
Collaborators: Pfizer
Conditions Neisseria Meningitidis
Enrollment 125 participants
Start Date 2025-11-04
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-22